Article Details

FDA Accepts Libtayo® (cemiplimab-rwlc) for Priority Review for Advanced Cervical Cancer ...

Retrieved on: 2021-09-28 10:52:30

Tags for this article:

Click the tags to see associated articles and topics

FDA Accepts Libtayo® (cemiplimab-rwlc) for Priority Review for Advanced Cervical Cancer .... View article details on hiswai:

Excerpt

Libtayo is a fully human monoclonal antibody targeting the PD-1 immune ... FDA-approved and authorized fully human monoclonal antibodies currently available ...

Article found on: pipelinereview.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up